Cochrane Review Group

Vascular

115 systematic reviews in Vascular ask 1,558 questions. 22.2% have no studies to answer them, 18% rest on very low certainty evidence and 23.4% reach moderate or high certainty.

Reviews

115

Questions

1,558

current versions

No studies

22.2%

Moderate or high

23.4%

No studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Vascular

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Intervention NR Failure of hemostatic intervention ( · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane	RR 0.46 [0.35, 0.61]	17 studies · 2120 participants	Very low
Intervention NR Death from bleeding complications (up to 30 days · vascular surgery patients who undergo creation of an anastomosis The role of sealants for achieving anastomotic hemostasis in vascular surgery (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Change in claudication distance from baseline (m) · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Amputation‐free survival · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Revascularisation‐free survival · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Major adverse limb events (MALE) · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Above‐ankle amputation · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane	no estimate extracted	NR	No studies
Supervised exercise therapy following vascular intervention vs vascular intervention alone MWD ‐ change from baseline · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane	no estimate extracted	2 studies · 89 participants	Very low
Supervised exercise therapy following vascular intervention vs vascular intervention alone 6MWT ‐ change from baseline · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane	no estimate extracted	1 study · 49 participants	Very low
Supervised exercise therapy following vascular intervention vs vascular intervention alone PFWD ‐ change from baseline · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane	no estimate extracted	2 studies · 87 participants	Very low
Supervised exercise therapy following vascular intervention vs vascular intervention alone ABI ‐ absolute value · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane	no estimate extracted	2 studies · 110 participants	Very low
Supervised exercise therapy following vascular intervention vs vascular intervention alone Mortality · people with symptomatic peripheral arterial disease§ Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic… (2024) · Cochrane	OR 0.92 [0.42, 2]	6 studies · 346 participants	Very low

Reviews 115

Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication

Hageman, D, Fokkenrood, HJP, et al. · Cochrane Database of Systematic Reviews · 2018

Vascular

Thinnest evidence

Reviews 115

Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication

Rutosides for treatment of post‐thrombotic syndrome

Prostanoids for critical limb ischaemia

Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism

Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb‐threatening ischaemia

Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non‐reconstructable peripheral arterial disease

Endovascular revascularisation versus conservative management for intermittent claudication

Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical lower limb ischaemia patients

Gene therapy for peripheral arterial disease

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies

Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease)

Exercise for intermittent claudication

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism

Bypass surgery for chronic lower limb ischaemia

Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism

Compression therapy for prevention of post‐thrombotic syndrome

Endovascular treatment for ruptured abdominal aortic aneurysm

Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism

Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients

Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm

Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism

Growth factors for angiogenesis in peripheral arterial disease

Neuromuscular electrical stimulation for the prevention of venous thromboembolism

Pentasaccharides for the treatment of deep vein thrombosis